166 related articles for article (PubMed ID: 37155946)
1. Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.
Lai C; Bhansali RS; Kuo EJ; Mannis G; Lin RJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390018. PubMed ID: 37155946
[TBL] [Abstract][Full Text] [Related]
2. A User's Guide to Novel Therapies for Acute Myeloid Leukemia.
Patel SA; Gerber JM
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):277-288. PubMed ID: 32113891
[TBL] [Abstract][Full Text] [Related]
3. [Novel Strategies to Treat Acute Myeloid Leukemia].
Gediga MHE; Middeke JM; Ruhnke L
Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117
[TBL] [Abstract][Full Text] [Related]
4. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS; Pratz KW; Lai C
J Hematol Oncol; 2023 Mar; 16(1):29. PubMed ID: 36966300
[TBL] [Abstract][Full Text] [Related]
6. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
Derman BA; Larson RA
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101102. PubMed ID: 31779969
[TBL] [Abstract][Full Text] [Related]
7. Emerging agents and regimens for AML.
Liu H
J Hematol Oncol; 2021 Mar; 14(1):49. PubMed ID: 33757574
[TBL] [Abstract][Full Text] [Related]
8. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia.
Stone RM; O'Donnell MR; Sekeres MA
Hematology Am Soc Hematol Educ Program; 2004; ():98-117. PubMed ID: 15561679
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
11. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
DeAngelo DJ; Stein EM; Ravandi F
Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
13. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
14. Advances in treatment formulations for acute myeloid leukemia.
Briot T; Roger E; Thépot S; Lagarce F
Drug Discov Today; 2018 Dec; 23(12):1936-1949. PubMed ID: 29870791
[TBL] [Abstract][Full Text] [Related]
15. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
[TBL] [Abstract][Full Text] [Related]
16. An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape.
Bystrom R; Levis MJ
Curr Oncol Rep; 2023 Apr; 25(4):369-378. PubMed ID: 36808557
[TBL] [Abstract][Full Text] [Related]
17. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
18. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
19. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
